MODERNA INC (0QF.DE) Stock Price, Quote, News and Overview
FRA:0QF - Deutsche Boerse Ag - US60770K1079 - Common Stock - Currency: EUR
0QF.DE Quote, Performance and Key Statistics
MODERNA INC
FRA:0QF (2/4/2025, 7:00:00 PM)
34.565
-1.66 (-4.58%)
The current stock price of 0QF.DE is 34.565 EUR. In the past month the price decreased by -23.36%. In the past year, price decreased by -57.66%.
0QF.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.64B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.99 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About 0QF.DE
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,600 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 5600
Company Website: https://www.modernatx.com/
Investor Relations: https://investors.modernatx.com/
Phone: 16177146500
0QF.DE FAQ
What is the stock price of 0QF.DE?
The current stock price of 0QF.DE is 34.565 EUR.
What is the symbol for MODERNA INC stock?
The exchange symbol of MODERNA INC is 0QF and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 0QF.DE stock listed?
0QF.DE stock is listed on the Deutsche Boerse Ag exchange.
Is 0QF.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for 0QF.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of 0QF.DE.
Does 0QF.DE stock pay dividends?
0QF.DE does not pay a dividend.
When does 0QF.DE stock report earnings?
0QF.DE will report earnings on 2025-02-14, after the market close.
What is the Price/Earnings (PE) ratio of 0QF.DE?
0QF.DE does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.63).
0QF.DE Technical Analysis
0QF.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 0QF.DE. The financial health of 0QF.DE is average, but there are quite some concerns on its profitability.
0QF.DE Financial Highlights
Over the last trailing twelve months 0QF.DE reported a non-GAAP Earnings per Share(EPS) of -5.63. The EPS decreased by 37.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.07% | ||
| ROE | -18.65% | ||
| Debt/Equity | 0.05 |
0QF.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 67% to 0QF.DE. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 24.44% and a revenue growth -50.04% for 0QF.DE